Management of Molluscum Contagiosum
For healthy children and adolescents with molluscum contagiosum, watchful waiting with spontaneous resolution is the recommended first-line approach, but active treatment should be strongly considered for cosmetically bothersome lesions, underlying eczema, or to prevent transmission and psychosocial distress 1.
Natural History and Decision Framework
Molluscum contagiosum is a benign, self-limited viral infection affecting 5-11% of children aged 0-16 years 1. The infection typically resolves spontaneously in 6-12 months, though complete resolution can take up to 4 years 1. While the "watch and wait" approach is common, this strategy carries important drawbacks: increased risk of viral transmission to others, prolonged infection duration, and significant psychosocial sequelae including anxiety, embarrassment, and social isolation 2.
When to Treat Actively
Active treatment is indicated for:
- Lesions in cosmetically bothersome locations (face, visible areas)
- Patients with underlying atopic dermatitis or eczema
- Symptomatic lesions (pain, itching, redness)
- Bacterial superinfection
- Prevention of transmission in contact sports or shared environments
- Patient/family preference to shorten disease course 1, 3
Treatment Options
First-Line Physical Treatments
Cryotherapy with liquid nitrogen and 10% potassium hydroxide have similar efficacy in children 1. However, cryotherapy carries risk of postinflammatory hyperpigmentation and, uncommonly, scarring 1—a critical consideration, especially in patients with darker skin tones.
Curettage (incision and curettage aggressive enough to cause bleeding) is effective and allows immediate lesion removal 4. This is particularly useful for isolated or few lesions.
Second-Line Options
Cantharidin shows promise in open-label and observational studies 1, though one small randomized trial (n=29) showed improvement over placebo that did not reach statistical significance 1. Despite limited high-quality evidence, many dermatologists use cantharidin effectively in clinical practice 5.
Treatments NOT Recommended
Imiquimod was NOT shown to be beneficial compared with placebo in randomized controlled trials 1. This is important because imiquimod is sometimes still prescribed despite lack of efficacy data.
Special Populations
Immunocompromised Patients
In immunocompromised individuals (HIV, organ transplant recipients), molluscum presents with widespread, persistent lesions requiring more aggressive treatment 2, 6. Options include cidofovir, imiquimod, or interferon, though evidence is limited 6.
Athletes and Contact Sports
For wrestlers and contact sport athletes, lesions should be covered or treated before return to competition 1. Specific return-to-play guidelines exist from NCAA, NFHS, and NATA 1.
Patients with Atopic Dermatitis
Children with eczema develop more widespread lesions complicated by dermatitis 3. These patients particularly benefit from active treatment to reduce symptom burden and prevent spread.
Critical Pitfalls to Avoid
- Don't assume all lesions will resolve quickly—up to 4 years is possible 1
- Don't use cryotherapy without discussing pigmentation risks, especially in darker skin types
- Don't prescribe imiquimod—it lacks efficacy evidence 1
- Don't ignore psychosocial impact—the "watch and wait" approach may cause significant distress 2
- In adults with extensive molluscum and minimal inflammation, consider immunocompromised state 4
Treatment Algorithm
For isolated/few lesions: Curettage or cryotherapy (with pigmentation counseling)
For multiple lesions or sensitive locations: 10% potassium hydroxide or cantharidin
For patients with atopic dermatitis: Prioritize active treatment; consider cantharidin or curettage to avoid irritation
For immunocompromised patients: Refer to dermatology for cidofovir, imiquimod, or interferon consideration
For all patients: Counsel on transmission prevention (avoid sharing towels, bathing together, contact sports participation until treated)
The decision between active treatment and observation should weigh the number and location of lesions, presence of symptoms or comorbidities, transmission risk, and patient/family preferences—but recognize that active treatment often provides faster resolution and reduces psychosocial burden 2, 5.